104 related articles for article (PubMed ID: 22627198)
21. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure.
Ljutić D; Cameron JS; Ogg CS; Turner C; Hicks JA; Owen WJ
QJM; 1994 Nov; 87(11):685-92. PubMed ID: 7820543
[TBL] [Abstract][Full Text] [Related]
23. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
24. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
25. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3.
Mizumoto D; Watanabe Y; Fukuzawa Y; Yuzawa Y; Yamazaki C
Nephrol Dial Transplant; 1994; 9(12):1751-8. PubMed ID: 7708259
[TBL] [Abstract][Full Text] [Related]
26. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain.
Yano S; Sugimoto T; Tsukamoto T; Yamaguchi T; Hattori T; Sekita KI; Kaji H; Hattori S; Kobayashi A; Chihara K
Horm Metab Res; 2003 Apr; 35(4):259-64. PubMed ID: 12778370
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
28. Increases in parathyroid hormone (PTH) after gastric bypass surgery appear to be of a secondary nature.
Jin J; Robinson AV; Hallowell PT; Jasper JJ; Stellato TA; Wilhem SM
Surgery; 2007 Dec; 142(6):914-20; discussion 914-20. PubMed ID: 18063076
[TBL] [Abstract][Full Text] [Related]
29. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation.
Tabibzadeh N; Karaboyas A; Robinson BM; Csomor PA; Spiegel DM; Evenepoel P; Jacobson SH; Ureña-Torres PA; Fukagawa M; Al Salmi I; Liang X; Pisoni RL; Young EW
Nephrol Dial Transplant; 2021 Jan; 36(1):160-169. PubMed ID: 33068419
[TBL] [Abstract][Full Text] [Related]
30. Effect of calcium-channel blockers on calcium-phosphate metabolism in patients with end-stage renal disease.
Lippuner K; Zehnder HJ; Casez JP; Takkinen R; Descoeudres C; Jaeger P
Nephrol Dial Transplant; 1996 Jan; 11(1):70-4. PubMed ID: 8649655
[TBL] [Abstract][Full Text] [Related]
31. Relationship of predialytic intact parathyroid hormone on secondary hyperparathyroidism in chronic maintenance haemodialysis patients.
Etoh S; Murata T; Hasegawa Y; Miyahara Y; Ishimura A; Abe Y; Noda R; Ogahara S; Kaneoka H; Saito T
Nephrology (Carlton); 2004 Jun; 9(3):161-6. PubMed ID: 15189177
[TBL] [Abstract][Full Text] [Related]
32. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
33. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
34. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
35. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Papapoulos SE; Harinck HI; Bijvoet OL; Gleed JH; Fraher LJ; O'Riordan JL
Bone Miner; 1986 Feb; 1(1):69-78. PubMed ID: 3508718
[TBL] [Abstract][Full Text] [Related]
36. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone.
Jean G; Mayor B; Hurot JM; Deleaval P; Lorriaux C; Zaoui E; Chazot C
Nephrol Dial Transplant; 2013 Jan; 28(1):176-82. PubMed ID: 22764192
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum parathormone level after "concise parathyroidectomy" for primary sporadic hyperparathyroidism.
Carty SE; Roberts MM; Virji MA; Haywood L; Yim JH
Surgery; 2002 Dec; 132(6):1086-92; discussion 1092-3. PubMed ID: 12490859
[TBL] [Abstract][Full Text] [Related]
38. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
39. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].
Karlsson SL; Indridason OS; Franzson L; Sigurdsson G
Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312
[TBL] [Abstract][Full Text] [Related]
40. Bone mineral disturbances in patients with chronic kidney disease stage 5 not yet on dialysis.
Marn Pernat A; Zrimšek M
Clin Nephrol; 2017 Supplement 1; 88(13):39-43. PubMed ID: 28619127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
